KR20040058103A - 신규 개질 방출 제제 - Google Patents

신규 개질 방출 제제 Download PDF

Info

Publication number
KR20040058103A
KR20040058103A KR10-2003-7010577A KR20037010577A KR20040058103A KR 20040058103 A KR20040058103 A KR 20040058103A KR 20037010577 A KR20037010577 A KR 20037010577A KR 20040058103 A KR20040058103 A KR 20040058103A
Authority
KR
South Korea
Prior art keywords
modified release
solid dispersion
release solid
dispersion formulation
multiparticulate modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR10-2003-7010577A
Other languages
English (en)
Korean (ko)
Inventor
안 우포
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20040058103A publication Critical patent/KR20040058103A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR10-2003-7010577A 2001-02-13 2002-02-08 신규 개질 방출 제제 Abandoned KR20040058103A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100478-7 2001-02-13
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE0100477-9 2001-02-13
PCT/SE2002/000228 WO2002064121A1 (en) 2001-02-13 2002-02-08 Novel modified released formulation

Publications (1)

Publication Number Publication Date
KR20040058103A true KR20040058103A (ko) 2004-07-03

Family

ID=26655389

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7010577A Abandoned KR20040058103A (ko) 2001-02-13 2002-02-08 신규 개질 방출 제제

Country Status (18)

Country Link
US (3) US20040067252A1 (enExample)
EP (2) EP1361868A1 (enExample)
JP (2) JP2004518708A (enExample)
KR (1) KR20040058103A (enExample)
CN (2) CN1491105A (enExample)
AT (1) ATE324871T1 (enExample)
AU (1) AU2002228579B2 (enExample)
BR (1) BR0206825A (enExample)
CA (2) CA2434542A1 (enExample)
DE (1) DE60211130T2 (enExample)
DK (1) DK1368006T3 (enExample)
ES (1) ES2261643T3 (enExample)
IL (1) IL157075A0 (enExample)
MX (1) MXPA03007092A (enExample)
NO (1) NO20033564L (enExample)
NZ (2) NZ526993A (enExample)
PT (1) PT1368006E (enExample)
WO (2) WO2002064118A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
BR0314787A (pt) * 2002-09-28 2005-07-26 Mcneil Ppc Inc Forma de dosagem de liberação modificada
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
HRP20141001T1 (hr) 2006-03-16 2014-12-05 Euro-Celtique S.A. Farmaceutski sferoidi
JP2011516412A (ja) 2008-03-05 2011-05-26 ビカス セラピューティクス，エルエルシー 癌および粘膜炎の治療のための組成物および方法
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途
EP2921486B1 (en) 2009-08-07 2017-09-27 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012070030A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
CA2859174C (en) 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
EP3319595A4 (en) * 2015-06-30 2019-04-03 Kemin Industries, Inc. ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
WO2021142395A1 (en) 2020-01-10 2021-07-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
US20250101427A1 (en) 2021-07-22 2025-03-27 The Regents Of The University Of California Compositions and methods for using purified human rna editing enzymes
WO2023184282A1 (en) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd X842 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL248553A (enExample) * 1959-02-18
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Also Published As

Publication number Publication date
CA2434835A1 (en) 2002-08-22
DE60211130T2 (de) 2006-11-30
ES2261643T3 (es) 2006-11-16
JP2004518709A (ja) 2004-06-24
EP1368006B1 (en) 2006-05-03
CA2434542A1 (en) 2002-08-22
HK1059740A1 (en) 2004-07-16
CN1491105A (zh) 2004-04-21
IL157075A0 (en) 2004-02-08
NZ526994A (en) 2005-01-28
US20040067256A1 (en) 2004-04-08
BR0206825A (pt) 2004-02-25
US20080118560A1 (en) 2008-05-22
PT1368006E (pt) 2006-08-31
EP1368006A1 (en) 2003-12-10
NZ526993A (en) 2005-01-28
NO20033564D0 (no) 2003-08-12
AU2002228579B2 (en) 2006-07-27
DE60211130D1 (de) 2006-06-08
MXPA03007092A (es) 2003-11-18
EP1361868A1 (en) 2003-11-19
WO2002064118A1 (en) 2002-08-22
CN1491104A (zh) 2004-04-21
WO2002064121A1 (en) 2002-08-22
US20040067252A1 (en) 2004-04-08
NO20033564L (no) 2003-10-02
JP2004518708A (ja) 2004-06-24
ATE324871T1 (de) 2006-06-15
DK1368006T3 (da) 2006-07-24

Similar Documents

Publication Publication Date Title
AU2002228579B2 (en) Novel modified released formulation
AU2002228579A1 (en) Novel modified released formulation
Paudwal et al. Recent advances in solid dispersion technology for efficient delivery of poorly water-soluble drugs
EP2136792B1 (en) Hot-melt micropellets
JP2009510138A (ja) 経口投与でき、かつ活性成分の迅速な放出を有する固形医薬投与形態
JP4856843B2 (ja) 新規フェノフィブラート錠剤
WO2007086689A1 (en) A solid dispersion comprising ubidecarenone, a process for preparing the same and a pharmaceutical composition comprising the same
NZ504353A (en) Porous greasy or non-greasy hydroxyapatite ceramic particles and a greasy, oily or sticky excipient as carriers for drug substances
JP2002517431A (ja) マイクロ浸透圧制御薬物送達システム
JP2018516942A (ja) 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
Pi et al. Polymer blends used to develop felodipine-loaded hollow microspheres for improved oral bioavailability
US8062664B2 (en) Process for preparing formulations of lipid-regulating drugs
JP4754485B2 (ja) 共沈活性物質含有粒子
HK1059740B (en) Novel modified released formulation
KR100546047B1 (ko) 디히드로피리딘계 화합물의 서방출성 제제 및 그 제조방법
AU2002230344A1 (en) Novel modified release formulation
WO2000032166A2 (en) Microparticles containing water insoluble active agents
US20060177512A1 (en) Process for preparing formulations of lipid-regulating drugs
EP1643975A2 (en) Process for preparing formulations of lipid-regulating drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20030812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20070124

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20071214

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20080701

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20071214

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20080731

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20080701

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20080911

Appeal identifier: 2008101007577

Request date: 20080731

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20080829

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20080731

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20080314

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070124

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20080911

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20080904

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee